Scarica l'app Stockscreener
4.575
2.81%
0.125
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.45
Aprire:
$4.5
Volume 24 ore:
852.95K
Relative Volume:
0.38
Capitalizzazione di mercato:
$421.71M
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-3.5192
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
-8.50%
1M Prestazione:
-7.01%
6M Prestazione:
-62.74%
1 anno Prestazione:
-83.51%
Intervallo 1D:
$4.47
$4.6599
Intervallo di 1 settimana:
$4.425
$5.195
Portata 52W:
$3.8119
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Confronta MYGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.575 | 481.17M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
428.30 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
190.06 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
533.40 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.83 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
188.32 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Is Myriad Genetics Inc. a good long term investmentHigh-performance investment picks - jammulinksnews.com
What drives Myriad Genetics Inc. stock priceMarket-beating returns - jammulinksnews.com
What analysts say about Myriad Genetics Inc. stockTremendous growth potential - Autocar Professional
Insider Sellers Might Regret Selling Myriad Genetics Shares at a Lower Price Than Current Market Value - simplywall.st
Volatile Stocks to Avoid: Williams-Sonoma, Timken, and Myriad Genetics - AInvest
Myriad Genetics Inc. Stock Analysis and ForecastRapid portfolio appreciation - jammulinksnews.com
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know - Yahoo Finance
Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com
Myriad Genetics Earns 2025 Great Place To Work Certification™ - The Manila Times
Myriad Genetics Outperforms Average US Company by 30% in Workplace Excellence - Stock Titan
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - MSN
Myriad Genetics (MYGN) Drops 3.85% Despite Expansion Efforts - AInvest
Parp Inhibitor Biomarkers Market Is Booming So Rapidly By 2032 | Myriad Genetics, Inc., F. Hoffmann-La Roche AG - openPR.com
Where are the Opportunities in (MYGN) - news.stocktradersdaily.com
5 Revealing Analyst Questions From Myriad Genetics’s Q1 Earnings Call - Yahoo Finance
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC - GlobeNewswire
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
Myriad Genetics at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com Canada
Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Consumer Genomics Market Is Booming So Rapidly 2025-2032 | Color - openPR.com
5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - Yahoo Finance
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire
7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire
Trend Tracker for (MYGN) - news.stocktradersdaily.com
US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire
US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo Finance
Myriad Genetics (MYGN) Launches FirstGene Multiple Prenatal Screen | MYGN Stock News - GuruFocus
Myriad Genetics Launches FirstGene™ Prenatal Screen for Comprehensive Genetic Risk Assessment in One Blood Draw - Nasdaq
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.89%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):